Abstract: The Nucleotide‐ binding oligomerization domain‐ like receptor‐ family pyrin domain‐ containing 3 (NLRP3) inflammasome is a crucial innate immune signaling complex that facilitates the release of IL-1β and IL-18 through the activation of caspase-1, thereby triggering inflammatory responses and pyroptosis. With extensive studies on the NLRP3 inflammasome, its aberrant activation has been identified as a key driver of the onset and progression of various liver diseases. Consequently, this review primarily focuses on the regulatory mechanisms of the NLRP3 inflammasome and summarizes recent research advances in viral hepatitis, non-alcoholic fatty liver disease, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, liver fibrosis, and hepatocellular carcinoma. Furthermore, it highlights the role of the NLRP3 inflammasome in liver diseases via the "gut liver axis" and its crosstalk with multiple signaling pathways, including TLR4/NF-κB, SIRT1/Nrf2, and FLI1/TGF-β/Smad. This review also systematically discusses therapeutic strategies targeting the NLRP3 inflammasome, providing novel insights into the development of synergistic therapies.